DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including REMOXY ER, an investigational extended release pain relief drug based on ORADUR technology; and POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Sandoz AG; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone408-777-1417
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$49.17 million
Profitability
Miscellaneous
Employees93
OptionableOptionable
DURECT (NASDAQ:DRRX) Frequently Asked Questions
What is DURECT's stock symbol?
DURECT trades on the NASDAQ under the ticker symbol "DRRX."
How were DURECT's earnings last quarter?
DURECT Co. (NASDAQ:DRRX) issued its quarterly earnings data on Wednesday, November, 7th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.02). The specialty pharmaceutical company had revenue of $8.04 million for the quarter, compared to the consensus estimate of $6.58 million. DURECT had a negative return on equity of 36.86% and a negative net margin of 28.39%. View DURECT's Earnings History.
When is DURECT's next earnings date?
What price target have analysts set for DRRX?
1 equities research analysts have issued 1-year price targets for DURECT's shares. Their predictions range from $3.00 to $3.00. On average, they expect DURECT's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 417.2% from the stock's current price. View Analyst Price Targets for DURECT.
What is the consensus analysts' recommendation for DURECT?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DURECT.
Has DURECT been receiving favorable news coverage?
Media headlines about DRRX stock have trended extremely positive on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. DURECT earned a media sentiment score of 4.1 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
Who are some of DURECT's key competitors?
Some companies that are related to DURECT include Cytokinetics (CYTK), TG Therapeutics (TGTX), Sinovac Biotech (SVA), Akebia Therapeutics (AKBA), Xeris Pharmaceuticals (XERS), Rigel Pharmaceuticals (RIGL), Abeona Therapeutics (ABEO), Keryx Biopharmaceuticals (KERX), Stemline Therapeutics (STML), Kindred Biosciences (KIN), Concert Pharmaceuticals (CNCE), Insys Therapeutics (INSY), ZIOPHARM Oncology (ZIOP), Evelo Biosciences (EVLO) and BioDelivery Sciences International (BDSI).
Who are DURECT's key executives?
DURECT's management team includes the folowing people:
- Dr. Felix Theeuwes, Co-Founder, Chairman & Distinguished Scientist (Age 81)
- Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 62)
- Mr. Matthew J. Hogan, CFO & Sec. (Age 59)
- Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 62)
- Mr. Michael H. Arenberg, Chief Financial Officer
Who are DURECT's major shareholders?
DURECT's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Gagnon Securities LLC (0.79%) and Virtu Financial LLC (0.04%). View Institutional Ownership Trends for DURECT.
Which major investors are selling DURECT stock?
Which major investors are buying DURECT stock?
How do I buy shares of DURECT?
Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DURECT's stock price today?
One share of DRRX stock can currently be purchased for approximately $0.58.
How big of a company is DURECT?
DURECT has a market capitalization of $93.99 million and generates $49.17 million in revenue each year. The specialty pharmaceutical company earns $-3,690,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis. DURECT employs 93 workers across the globe.
What is DURECT's official website?
How can I contact DURECT?
DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.
MarketBeat Community Rating for DURECT (NASDAQ DRRX)
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
